Dual‐Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H 2 Burst and Cascade Catalytic ROS Birth to Repress Cancer
Advanced Materials · 2026-01 · 38 (4)
DOI: 10.1002/adma.202516305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 21.10.2025. Verfasst von Duo Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Department of Ultrasound, Department of Hepatobiliary Surgery, Department of Gastrointestinal Surgery, Guangxi Medical Unive…. Hauptthemen laut MEDLINE: Hydrogen, Reactive Oxygen Species, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Guangxi Key Technologies R&D Program, Guangxi Natural Science Foundation Key Project, Guangxi Clinical Research Center for Medical Imaging Construction.
Abstract (Originalsprache)
Single or combined ROS therapy will induce cancer resistance after long‐term medication cure. Although currently concurrent H 2 /ROS therapy is a promising method, the mutual reaction between H 2 and ROS dampens their efficiency. To address this issue, g‐C 3 N 4 ‐based dual‐heterojunctions, i.e., N‐doped carbon nanoribbons (N‐CNB)/g‐C 3 N 4 and core–shell‐structured Au@Pd nanoparticles/g‐C 3 N 4 , respectively, are constructed to decode alternate H 2 /ROS therapy. Therein, N‐CNB/g‐C 3 N 4 heterojunctions enhance near‐infrared (NIR) photoabsorption to unlock photocatalytic H 2 evolution, and Au@Pd/g‐C 3 N 4 heterojunctions unlock the inherent and newly‐emerging bioenzymes‐like catalytic ROS birth. In this alternate H 2 /ROS therapy, photocatalytic H 2 evolution and multienzymically‐catalytic ROS birth are alternately decoded under NIR “on” and “off”, respectively, because the photoirradiation‐triggered structural shift insensitive to photothermal effects is reversible in response to NIR “on” and “off”, displaying a temporal controllability. The alternate H 2 /ROS therapy expedites the infiltrations and intratumoral proliferation of anti‐tumor immune cells including CTLs and Th17, hampers the infiltrations of exhausted CD8+ T cells and Tregs, and downregulates resistance‐associated proteins (PARP, EpCAM, and CD133). These actions cooperatively activate robust immune responses, attenuate anti‐tumor immunity confinements, and cancer resistance to suppress common and Sorafenib‐induced resistant liver cancer. This work offers distinctive insights into cancer resistance removal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Department of Ultrasound, Department of Hepatobiliary Surgery, Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, N…
- Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, No. 87 Ding-Jia-Qiao Road, Nanjing, Jiangsu, 210009, China.
- Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Key Laboratory of Regenerative Medicine & Key Laboratory…
- Guangxi Colleges and Universities Key Laboratory of Biological Molecular Medicine Research & Guangxi Key Laboratory of Brain Science, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, G…
- Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, No. 6 Shuangyong Road, Nanning, Guangxi, 530021, China.
- Department of Orthopedics and Central Laboratory, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, West Sec…
ORCID-Profile: Kun Zhang
Förderung
- Guangxi Key Technologies R&D Program
- Guangxi Natural Science Foundation Key Project
- Guangxi Clinical Research Center for Medical Imaging Construction
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wang, D., Qiu, G., Wang, H., Zheng, L., Zhang, X., Li, Z., Zuo, M., Wang, X., Zhou, N., Xiao, L., Liu, J., Luo, T., Liu, S., & Zhang, K. (2026). Dual‐Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H 2 Burst and Cascade Catalytic ROS Birth to Repress Cancer. Advanced Materials, 38(4). https://doi.org/10.1002/adma.202516305
Vancouver
Wang D, Qiu G, Wang H, Zheng L, Zhang X, Li Z, et al. Dual‐Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H 2 Burst and Cascade Catalytic ROS Birth to Repress Cancer. Advanced Materials. 2026;38(4). doi:10.1002/adma.202516305
BibTeX
@article{Wang2026,
author = {Wang, Duo and Qiu, Guanhua and Wang, Hong and Zheng, Liyao and Zhang, Xiaoqian and Li, Zelun and Zuo, Maocheng and Wang, Xiaobo and Zhou, Niqiang and Xiao, Lujia and Liu, Junjie and Luo, Tao and Liu, Sijia and Zhang, Kun},
title = {Dual‐Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H 2 Burst and Cascade Catalytic ROS Birth to Repress Cancer},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {4},
doi = {10.1002/adma.202516305}
}
EUVIMED